טוען...
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185(her2/neu) and the EGFR–p185(her2/neu) complexes
2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2819401/ https://ncbi.nlm.nih.gov/pubmed/18264138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2008.13 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|